An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

Dengue is caused by a mosquito-transmitted flavivirus. The disease is now endemic to many tropical and subtropical regions, manifesting as approximately 96 million symptomatic cases of dengue each year. Clinical trials have shown TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, to be...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Sanjay S. Patel, Peter Winkle, Alice Faccin, Francesco Nordio, Inge LeFevre, Claudia Galindo Tsoukas
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Taylor & Francis Group 2023-08-01
Цуврал:	Human Vaccines & Immunotherapeutics
Нөхцлүүд:	dengue fever immunogenicity live attenuated safety shelf-life tetravalent dengue vaccine
Онлайн хандалт:	http://dx.doi.org/10.1080/21645515.2023.2254964
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!